Literature DB >> 24962738

Prescription patterns for tuberculosis treatment and adherence to treatment guidelines: a population-based study in Taiwan.

Shiow-Ing Wang1, Gwan-Han Shen, Hui-Chung Shi, Shang-Jyh Chiou.   

Abstract

PURPOSE: Tuberculosis is a health threat in Taiwan. Previous research is mainly focused on patients' compliance, and research on medicines prescribed by physicians is limited. This study endeavors to present the prescription patterns of Tuberculosis treatment and its adherence to the guidelines.
METHODS: Newly diagnosed Tuberculosis patients in 2008 were selected from the National Health Insurance claims database. We divided prescriptions into standard prescriptions, non-standard prescriptions, and second-line medicines on the basis of the fourth edition of Taiwan's guidelines for the diagnosis and treatment of Tuberculosis. We first described the distribution of these prescriptions of TB regimen in the first 2 months among the new patients. Furthermore, a graphical presentation was used to visualize physician's complex prescription behavior.
RESULTS: In total, 11,164 patients were included in this analysis; 28,291 prescriptions were prescribed during the first 2 months after diagnosis. Among these prescriptions, 53.34% were standard prescriptions, 45.81% were non-standard prescriptions, and 0.84% were second-line medicines. Prescribing medicines for 28 days at the first visit was the most common scenario. Approximately 35 patterns can be derived from the prescriptions in Taiwan.
CONCLUSIONS: The prescriptions suggested in the guideline are considered to have better therapeutic effects. However, this study revealed that approximately 55% prescriptions adhered to the regimen recommended by the guidelines. The Pharmacoepidemiology and Drug Safety results of this study can help to explore possible reasons to the poor control of the disease.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  guidelines adherence; pharmacoepidemiology; prescriptions; tuberculosis

Mesh:

Substances:

Year:  2014        PMID: 24962738     DOI: 10.1002/pds.3665

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  4 in total

1.  Anti-tuberculosis treatments and risk of hepatocellular carcinoma in tuberculosis patients with liver cirrhosis: a population-based case-control study.

Authors:  Y-P Lim; C-L Lin; D-Z Hung; Y-N Lin; C-H Kao
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-09-27       Impact factor: 3.267

2.  Association of Antituberculosis Treatment and Lower Risk of Hyperlipidemia in Taiwanese Patients: A Population-Based Case-Control Study.

Authors:  Ying-Ray Lee; N I Tien; Cheng-Li Lin; Hsin-Yi Shen; DA-Tian Bau; Yun-Ping Lim
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

3.  Use of anti-tuberculosis drugs among newly diagnosed pulmonary tuberculosis inpatients in China: a retrospective study.

Authors:  Fei Huang; Hui Zhang; Qing Lv; Kaori D Sato; Yan Qu; Shitong Huan; Jun Cheng; Fei Zhao; Lixia Wang
Journal:  Infect Dis Poverty       Date:  2016-01-21       Impact factor: 4.520

4.  Efficacy, safety and prognosis of treating neurological deficits caused by spinal tuberculosis within 4 weeks' standard anti-tuberculosis treatment: A single medical center's experience.

Authors:  Chen-Guang Jia; Jian-Guo Gao; Feng-Sheng Liu; Zhuo Li; Zhao-Liang Dong; Li-Ming Yao; Lian-Bo Wang; Xiao-Wei Yao
Journal:  Exp Ther Med       Date:  2019-11-27       Impact factor: 2.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.